摘要
目的探讨血必净注射液对急性冠脉综合征患者炎症递质以及预后的影响。方法将2005年4月—2009年2月收入我院心内科90例患者随机分为治疗组46例和对照组44例,对照组按照常规治疗,治疗组在对照组的基础上加用血必净注射液50 mL,每日2次,治疗7 d。采用ELISA法检测IL-6、IL-10、CRP。记录患者28 d主要心血管事件发生率。结果疗程结束时治疗组IL-6、CRP明显低于对照组(P<0.05,P<0.01),IL-10高于对照组(P<0.05);治疗组心绞痛恶化率(4%)、心肌梗死发生率(2%)较对照组(18%,16%)明显降低(P均<0.05),对照组28 d病死率(14%)高于治疗组(4%),但无显著性差异。结论血必净注射液能改善急性冠脉综合征预后,其机制可能为通过调控炎症反应实现。
Objective It is to approach the influence of Xuebijing injection on inflammatory mediators and prognosis in patients with acute coronary syndrome （ACS）. Methods From April 2005 to February 2009, 90 patients diagnosed as ACS in department of cardiology in our hospital were divided into treatment group （ n = 46 ） and control group （ n = 44 ）. Control group was treated with routine treatment, while treatment group was treated with Xuebijing injection twice a day for seven days based on control group. The levels of IL- 6, IL- 10 and CRP were detected with ELISA assay. The incidence rate of main cardiovascular lesion in the patients in 28 days was recorded. Results The levels of IL- 6 and CRP in treatment group after treatment were obviously lower than those in control group （P〈0.05, P〈0.01）, while the level of IL- 10 in treatment group was higher than that in control group （P〈0.05）. The aggravation rate of angina pectoris （4%） and the incidence rate of myocardial infarction （2 % ） in treatment group were both obviously lower than those in control group （18 %, 16% ）（P〈0.05）. The fatality rate in 28 days in control group （14%） was higher than that in treatment group （4%）, but there was no significant difference. Conclusion Xuebijing injection can improve the prognosis of ACS patients and the mechanism may be adjusting inflammatory reaction.
出处
《现代中西医结合杂志》
CAS
2009年第29期3529-3530,3534,共3页
Modern Journal of Integrated Traditional Chinese and Western Medicine
基金
江苏省"333高层次人才培养工程"基金资助项目(2007-58)
关键词
血必净注射液
炎症递质
急性冠脉综合征
Xuebijing injection
inflammatory mediator
acute coronary syndrome
